标题：阿帕替尼联合用药治疗晚期胃癌的研究进展

      作者：倪晶 综述 王真 审校    南京市江宁区中医医院肿瘤内科，江苏 南京 211100

      卷次： 2021年32卷4期

      【摘要】 胃癌作为临床常见的一种恶性肿瘤，由于早期诊断率低，大多数患者发现时已属中晚期，丧失最佳手术机会。阿帕替尼作为我国自主研发的抗血管生成抑制剂，目前已广泛应用于晚期胃癌的治疗中。阿帕替尼联合用药治疗晚期胃癌，往往有增效减毒的作用。本文将近年来阿帕替尼联合用药治疗晚期胃癌的最新研究进展做一综述。
      【关键词】 晚期胃癌；阿帕替尼；靶向治疗；联合用药；治疗；进展
      【中图分类号】 R735.2 【文献标识码】 A 【文章编号】 1003—6350（2021）04—0507—04

Research progress of apatinib combined therapy for advanced gastric cancer.
NI Jing, WANG Zhen. JiangningDistrict Chinese Medicine Hospital, Nanjing 211100, Jiangsu, CHINA【Abstract】 Gastric cancer is a common clinical malignant tumor. Due to its low early diagnosis rate, most pa-tients are already in the middle and advanced stages when discovered, so as to lose the best opportunity for surgery. Apa-tinib, as an anti-angiogenic inhibitor independently developed in China, has been widely used in the treatment of ad-vanced gastric cancer. The combination of apatinib in the treatment of advanced gastric cancer often has the effect of syn-ergism and detoxification. This article reviews the latest research progress of apatinib in the treatment of advanced gas-tric cancer in recent years.
      【Key words】 Advanced gastric cancer; Apatinib; Targeted therapy; Combined medication; Treatment; Progress·综述·doi:10.3969/j.issn.1003-6350.2021.04.027基金项目：江苏省南京市江宁区区级课题(编号：2020SHSY0059)